BCMA Antibody
| Code | Size | Price |
|---|
| PSI-2397-0.02mg | 0.02mg | £150.00 |
Quantity:
| PSI-2397-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunofluorescence (IF)
- Immunohistochemistry (IHC)
- Western Blot (WB)
Documents
Further Information
Additional Names:
BCMA Antibody: BCM, BCMA, CD269, TNFRSF13A, BCM, Tumor necrosis factor receptor superfamily member 17, B-cell maturation protein
Application Note:
BCMA antibody can be used for detection of BCMA by Western blot at 5 μg/mL. Antibody can also be used for immunohistochemistry starting at 5 μg/mL. For immunofluorescence start at 20 μg/mL.
Antibody validated: Western Blot in human samples; Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Antibody validated: Western Blot in human samples; Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Background:
BCMA Antibody: Members in the TNF superfamily regulate immune responses and induce apoptosis. Two novel members in the TNF family were recently identified and designated BAFF/BLyS/TALL-1/THANK/zTNF4 and April/TALL-2, respectively. BAFF was characterized as a B cell activator since it induced B cell proliferation and immunoglobulin secretion. April regulates immunological and non-immunological cell growth. Three receptors, BCMA (for B cell maturation protein), TACI, and BAFF-R, for BAFF were recently identified. BCMA, like TACI, binds BAFF and April. BAFF and its receptors induce B cell development and survival, activate NF-κB and c-jun N-terminal kinase, and are involved in B cell associated autoimmune diseases.
Background References:
- Moore PA, Belvedere O, Orr A, et al. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 1999; 285:260-3
- Schneider P, MacKay F, Steiner V, et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J. Exp. Med. 1999; 189:1747-56
- Shu HB, Hu WH, Johnson H. TALL-1 is a novel member of the TNF family that is down-regulated by mitogens. J. Leukoc. Biol. 1999; 65:680-3
- Mukhopadhyay A, Ni J, Zhai Y, et al. Identification and characterization of a novel cytokine, THANK, a TNF homologue that activates apoptosis, nuclear factor-κB, and c-Jun NH2-terminal kinase. J. Biol. Chem. 1999; 274:15978-81
Buffer:
BCMA Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Immunogen:
BCMA antibody was raised against a 16 amino acid synthetic peptide mapping at the carboxy terminus of human BCMA.
The immunogen is located within the last 50 amino acids of BCMA.
The immunogen is located within the last 50 amino acids of BCMA.
NCBI Gene ID #:
608
NCBI Official Name:
tumor necrosis factor receptor superfamily, member 17
NCBI Official Symbol:
TNFRSF17
NCBI Organism:
Homo sapiens
Physical State:
Liquid
PREDICTED MOLECULAR WEIGHT:
Predicted: 20 kDa
Observed: 27 kDa
Observed: 27 kDa
Protein Accession #:
NP_001183
Protein GI Number:
23238192
Purification:
BCMA Antibody is affinity chromatography purified via peptide column.
Research Area:
Cytokine,Cancer
Swissprot #:
Q02223
User NOte:
Optimal dilutions for each application to be determined by the researcher.
Related Products
| Product Name | Product Code | Supplier | BCMA Peptide | PSI-2397P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|